CagriSema vs Pancragen
A side-by-side research comparison of CagriSema and Pancragen across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | CagriSema | Pancragen |
|---|---|---|
| Full name | CagriSema (Cagrilintide + Semaglutide) | Pancragen (Lys-Glu-Asp-Trp Pancreas Bioregulator) |
| Category | Weight Management | Weight Management |
| Status | Phase 3 Clinical Trial | Research compound (peptide bioregulator) |
| Mechanism | Dual-pathway activation: cagrilintide mimics amylin to activate area postrema satiety centers, while semaglutide activates GLP-1 receptors for complementary appetite suppression. | As a signal peptide (Lys-Glu-Asp-Trp), it is proposed to regulate gene expression in pancreatic tissue, supporting normal endocrine and exocrine pancreatic function and carbohydrate metabolism. |
| Molecular weight | Combination product | ~575 Da |
| Half-life | 7 days (both components) | Short (peptide) |
| Bioavailability | High (SubQ) | Oral (encapsulated) or subcutaneous |
| Typical dose | Cagrilintide 2.4mg + Semaglutide 2.4mg | ~1-2 capsules/day or short injectable courses |
| Frequency | Once weekly | Once daily |
| Route | Subcutaneous | Oral capsule or subcutaneous |
CagriSema reported benefits
- Enhanced weight loss vs monotherapy
- Dual appetite suppression
- Convenient single injection
- Improved metabolic parameters
- Potential 20-25% weight loss
Pancragen reported benefits
- Pancreatic tissue support
- Carbohydrate metabolism support (proposed)
- Metabolic resilience
- Short course-based protocol
Related comparisons
Research and educational reference only. Not medical advice.